title: Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation.
authors.affiliation: Department of Hematology, Oncology and Transplantation.
authors.forename: F
authors.initials: F
authors.lastname: Khan
authors.forename: M A
authors.initials: MA
authors.lastname: Linden
authors.forename: N D
authors.initials: ND
authors.lastname: Zantek
authors.forename: G M
authors.initials: GM
authors.lastname: Vercellotti
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001787:Blood Group Incompatibility / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D011719:Pyrazines / Q000008:administration & dosage*; D012010:Red-Cell Aplasia, Pure / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib